摘要
目的分析口服卡马西平(CBZ)对患者血浆纤维蛋白原含量的影响。方法回顾性分析我院收治的使用卡马西平出现血浆纤维蛋白原含量降低患者的临床资料,对患者的性别、年龄、卡马西平的用法用量、用药时间、停药时间、停药前后纤维蛋白原的含量变化及转归进行分析讨论。结果 12例男性患者均为长期不规则服药,时长与病史年限大致相同。经停用卡马西平,11例患者纤维蛋白原恢复至2.0g/L以上,1例停药14d,纤维蛋白原由1.40gL升至1.92g/L。结论卡马西平可致患者血浆纤维蛋白原含量降低,用药过程中应监测纤维蛋白原含量,以防引起严重出血。
Objective To analyze the effect of oral administration with Carbamazepine （CBZ） on plasma fibrinogen content for epilepsy patients. Methods The clinical data of patients with CBZ reduced plasma fibrinogen levels in patients were analyzed retrospectively. The patient ＇s sex, age, use of CBZ dosage, administration time, stop medicine time, fibrinogen levels before and after drug withdrawal and the prognosis were analyzed and compared. Results 12 male patients in long-term irregular medication, whose duration and medical history were approximately same. The disabled and symptomatic treatment of CBZ, 11 patients recovered to fibrinogen 2.0 g/L or more, one case of withdrawal 14 d and fibrinogen by the 1. 40 g/L increased to 1.92 g/L. Conclusion CBZ may cause decreased plasma fibrinogen levels, should be monitored during the medication, to prevent serious bleeding.
出处
《临床神经外科杂志》
CAS
2011年第1期36-37,共2页
Journal of Clinical Neurosurgery
